Sandbox Myopathy: Difference between revisions

Jump to navigation Jump to search
Line 27: Line 27:


==Differentiating Various Muscle Weakness==
==Differentiating Various Muscle Weakness==
{| class="wikitable"
{|
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Organ system
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Organ system
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! rowspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
Line 37: Line 37:
|-
|-
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia  
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia  
Line 54: Line 54:
! rowspan="3" style="background:#DCDCDC;" align="center" + |Medication−induced
! rowspan="3" style="background:#DCDCDC;" align="center" + |Medication−induced
! style="background:#DCDCDC;" align="center" + |[[Corticosteroids]]<ref name="pmid24083177">{{cite journal |vauthors=Gupta A, Gupta Y |title=Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment |journal=Indian J Endocrinol Metab |volume=17 |issue=5 |pages=913–6 |date=September 2013 |pmid=24083177 |pmc=3784879 |doi=10.4103/2230-8210.117215 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Corticosteroids]]<ref name="pmid24083177">{{cite journal |vauthors=Gupta A, Gupta Y |title=Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment |journal=Indian J Endocrinol Metab |volume=17 |issue=5 |pages=913–6 |date=September 2013 |pmid=24083177 |pmc=3784879 |doi=10.4103/2230-8210.117215 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 90: Line 88:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Statins]]<ref name="pmid22001973">{{cite journal |vauthors=Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ |title=Statin-induced myopathies |journal=Pharmacol Rep |volume=63 |issue=4 |pages=859–66 |date=2011 |pmid=22001973 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Statins]]<ref name="pmid22001973">{{cite journal |vauthors=Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ |title=Statin-induced myopathies |journal=Pharmacol Rep |volume=63 |issue=4 |pages=859–66 |date=2011 |pmid=22001973 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |60+
* 60+
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 122: Line 118:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Alcohol]]<ref name="pmid11784353">{{cite journal |vauthors=Preedy VR, Adachi J, Ueno Y, Ahmed S, Mantle D, Mullatti N, Rajendram R, Peters TJ |title=Alcoholic skeletal muscle myopathy: definitions, features, contribution of neuropathy, impact and diagnosis |journal=Eur. J. Neurol. |volume=8 |issue=6 |pages=677–87 |date=November 2001 |pmid=11784353 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Alcohol]]<ref name="pmid11784353">{{cite journal |vauthors=Preedy VR, Adachi J, Ueno Y, Ahmed S, Mantle D, Mullatti N, Rajendram R, Peters TJ |title=Alcoholic skeletal muscle myopathy: definitions, features, contribution of neuropathy, impact and diagnosis |journal=Eur. J. Neurol. |volume=8 |issue=6 |pages=677–87 |date=November 2001 |pmid=11784353 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 156: Line 150:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 176: Line 170:
! rowspan="6" style="background:#DCDCDC;" align="center" + |Endocrine
! rowspan="6" style="background:#DCDCDC;" align="center" + |Endocrine
! style="background:#DCDCDC;" align="center" + |[[Cushing's disease]]<ref name="pmid25221399">{{cite journal |vauthors=Sharma V, Borah P, Basumatary LJ, Das M, Goswami M, Kayal AK |title=Myopathies of endocrine disorders: A prospective clinical and biochemical study |journal=Ann Indian Acad Neurol |volume=17 |issue=3 |pages=298–302 |date=July 2014 |pmid=25221399 |pmc=4162016 |doi=10.4103/0972-2327.138505 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Cushing's disease]]<ref name="pmid25221399">{{cite journal |vauthors=Sharma V, Borah P, Basumatary LJ, Das M, Goswami M, Kayal AK |title=Myopathies of endocrine disorders: A prospective clinical and biochemical study |journal=Ann Indian Acad Neurol |volume=17 |issue=3 |pages=298–302 |date=July 2014 |pmid=25221399 |pmc=4162016 |doi=10.4103/0972-2327.138505 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |25 −45
* 25 −45
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 221: Line 213:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Adrenal insufficiency]]<ref name="pmid30656022">{{cite journal |vauthors=Ruff RL, Weissmann J |title=Endocrine myopathies |journal=Neurol Clin |volume=6 |issue=3 |pages=575–92 |date=August 1988 |pmid=3065602 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Adrenal insufficiency]]<ref name="pmid30656022">{{cite journal |vauthors=Ruff RL, Weissmann J |title=Endocrine myopathies |journal=Neurol Clin |volume=6 |issue=3 |pages=575–92 |date=August 1988 |pmid=3065602 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |30−50 years
* 30−50 years
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
Line 260: Line 250:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Hyperaldosteronism]] with myopathy<ref name="pmid5037033">{{cite journal |vauthors=Sambrook MA, Heron JR, Aber GM |title=Myopathy in association with primary hyperaldosteronism |journal=J. Neurol. Neurosurg. Psychiatry |volume=35 |issue=2 |pages=202–7 |date=April 1972 |pmid=5037033 |pmc=494037 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Hyperaldosteronism]] with myopathy<ref name="pmid5037033">{{cite journal |vauthors=Sambrook MA, Heron JR, Aber GM |title=Myopathy in association with primary hyperaldosteronism |journal=J. Neurol. Neurosurg. Psychiatry |volume=35 |issue=2 |pages=202–7 |date=April 1972 |pmid=5037033 |pmc=494037 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |50
* 50
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>distal
| colspan="2" |
* Proximal  
 
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 293: Line 279:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Hyperthyroidism]]<ref name="pmid28746208">{{cite journal |vauthors=Li Q, Liu Y, Zhang Q, Tian H, Li J, Li S |title=Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: A case report |journal=Medicine (Baltimore) |volume=96 |issue=30 |pages=e7591 |date=July 2017 |pmid=28746208 |pmc=5627834 |doi=10.1097/MD.0000000000007591 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Hyperthyroidism]]<ref name="pmid28746208">{{cite journal |vauthors=Li Q, Liu Y, Zhang Q, Tian H, Li J, Li S |title=Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: A case report |journal=Medicine (Baltimore) |volume=96 |issue=30 |pages=e7591 |date=July 2017 |pmid=28746208 |pmc=5627834 |doi=10.1097/MD.0000000000007591 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |40
* 40
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 323: Line 307:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Hypothyroidism]]<ref name="pmid6627693">{{cite journal |vauthors=Khaleeli AA, Griffith DG, Edwards RH |title=The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle |journal=Clin. Endocrinol. (Oxf) |volume=19 |issue=3 |pages=365–76 |date=September 1983 |pmid=6627693 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Hypothyroidism]]<ref name="pmid6627693">{{cite journal |vauthors=Khaleeli AA, Griffith DG, Edwards RH |title=The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle |journal=Clin. Endocrinol. (Oxf) |volume=19 |issue=3 |pages=365–76 |date=September 1983 |pmid=6627693 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |55
* >55
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 352: Line 334:
|-
|-
! style="background:#DCDCDC;" align="center" + |Diabetic infraction<ref name="pmid25932331">{{cite journal |vauthors=Horton WB, Taylor JS, Ragland TJ, Subauste AR |title=Diabetic muscle infarction: a systematic review |journal=BMJ Open Diabetes Res Care |volume=3 |issue=1 |pages=e000082 |date=2015 |pmid=25932331 |pmc=4410119 |doi=10.1136/bmjdrc-2015-000082 |url=}}</ref>  
! style="background:#DCDCDC;" align="center" + |Diabetic infraction<ref name="pmid25932331">{{cite journal |vauthors=Horton WB, Taylor JS, Ragland TJ, Subauste AR |title=Diabetic muscle infarction: a systematic review |journal=BMJ Open Diabetes Res Care |volume=3 |issue=1 |pages=e000082 |date=2015 |pmid=25932331 |pmc=4410119 |doi=10.1136/bmjdrc-2015-000082 |url=}}</ref>  
|
| style="background:#F5F5F5;" align="center" + |45 
* 45 
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
Line 388: Line 368:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 408: Line 388:
! rowspan="5" style="background:#DCDCDC;" align="center" + |Inflammatory/ Rheumatologic
! rowspan="5" style="background:#DCDCDC;" align="center" + |Inflammatory/ Rheumatologic
! style="background:#DCDCDC;" align="center" + |[[Dermatomyositis]]<ref name="pmid1658649">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
! style="background:#DCDCDC;" align="center" + |[[Dermatomyositis]]<ref name="pmid1658649">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
|
| style="background:#F5F5F5;" align="center" + |40s−50s<br>Can affect children
* 40s−50s
| style="background:#F5F5F5;" align="center" + |Proximal
* Can affect childreen
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 446: Line 423:
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Polymyositis]]<ref name="pmid16586492">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
! style="background:#DCDCDC;" align="center" + |[[Polymyositis]]<ref name="pmid16586492">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
|
| style="background:#F5F5F5;" align="center" + |> 18 years  
* > 18 years  
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
Line 458: Line 433:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
|
| style="background:#F5F5F5;" align="left" + |
* Similar to [[dermatomyositis]] without [[mucous]] and [[skin]] involvement
* Similar to [[dermatomyositis]] without [[mucous]] and [[skin]] involvement
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑''' [[Erythrocyte sedimentation rate|ESR]]
* '''↑↑''' [[Erythrocyte sedimentation rate|ESR]]
* '''↑↑''' [[C-reactive protein|CRP]]
* '''↑↑''' [[C-reactive protein|CRP]]
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|
| style="background:#F5F5F5;" align="left" + |
* Endomysial mononuclear infiltrate  
* Endomysial mononuclear infiltrate  
* Patchy necrosis  
* Patchy necrosis  
|-
|-
! style="background:#DCDCDC;" align="center" + |Inclusion body [[myositis]]<ref name="pmid16586493">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
! style="background:#DCDCDC;" align="center" + |Inclusion body [[myositis]]<ref name="pmid16586493">{{cite journal| author=Dalakas MC| title=Polymyositis, dermatomyositis and inclusion-body myositis. | journal=N Engl J Med | year= 1991 | volume= 325 | issue= 21 | pages= 1487-98 | pmid=1658649 | doi=10.1056/NEJM199111213252107 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1658649  }}</ref>
|
| style="background:#F5F5F5;" align="center" + |50s  
* 50s  
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>distal
| colspan="2" |
* Proximal
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 487: Line 459:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Dysphagia]]
* [[Dysphagia]]
* Asymmetric weakness
* Asymmetric weakness
|
| style="background:#F5F5F5;" align="left" + |
* [[Retrovirus]] (most common)
* [[Retrovirus]] (most common)
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* Antibodies to cytoplasmic 5'−nucleotidase
* Antibodies to cytoplasmic 5'−nucleotidase
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|
| style="background:#F5F5F5;" align="left" + |
* [[Inflammatory cells]]  
* [[Inflammatory cells]]  
* Invading [[muscle cells]]  
* Invading [[muscle cells]]  
* Vacuolar degeneration
* Vacuolar degeneration
* Inclusions or plaques  
* Inclusions or plaques  
|
| style="background:#F5F5F5;" align="left" + |
* [[Neurogenic]]
* [[Neurogenic]]
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Fibromyalgia]]<ref name="pmid27803417">{{cite journal |vauthors=Ohara N, Katada S, Yamada T, Mezaki N, Suzuki H, Suzuki A, Hanyu O, Yoneoka Y, Kawachi I, Shimohata T, Kakita A, Nishizawa M, Sone H |title=Fibromyalgia in a Patient with Cushing's Disease Accompanied by Central Hypothyroidism |journal=Intern. Med. |volume=55 |issue=21 |pages=3185–3190 |date=2016 |pmid=27803417 |pmc=5140872 |doi=10.2169/internalmedicine.55.5926 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Fibromyalgia]]<ref name="pmid27803417">{{cite journal |vauthors=Ohara N, Katada S, Yamada T, Mezaki N, Suzuki H, Suzuki A, Hanyu O, Yoneoka Y, Kawachi I, Shimohata T, Kakita A, Nishizawa M, Sone H |title=Fibromyalgia in a Patient with Cushing's Disease Accompanied by Central Hypothyroidism |journal=Intern. Med. |volume=55 |issue=21 |pages=3185–3190 |date=2016 |pmid=27803417 |pmc=5140872 |doi=10.2169/internalmedicine.55.5926 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |40−50s  
* 40−50s  
| style="background:#F5F5F5;" align="center" + |Generalized
| colspan="2" |
* Generalized
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
Line 519: Line 489:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
|
| style="background:#F5F5F5;" align="left" + |
* [[Anxiety]] or depression features
* [[Anxiety]] or depression features
* [[Fatigue]]  
* [[Fatigue]]  
Line 525: Line 495:
* [[Numbness]]  
* [[Numbness]]  
* [[Muscle spasms]]  
* [[Muscle spasms]]  
|
| style="background:#F5F5F5;" align="left" + |
* History of [[depression]]  
* History of [[depression]]  
|
| style="background:#F5F5F5;" align="left" + |
* [[Tenderness]] in the soft tissue anatomical location  
* [[Tenderness]] in the soft tissue anatomical location  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Polymyalgia rheumatica|Polymyalgia Rheumatica]]<ref name="pmid8948307">{{cite journal| author=Myklebust G, Gran JT| title=A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. | journal=Br J Rheumatol | year= 1996 | volume= 35 | issue= 11 | pages= 1161-8 | pmid=8948307 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8948307  }}</ref>
! style="background:#DCDCDC;" align="center" + |[[Polymyalgia rheumatica|Polymyalgia Rheumatica]]<ref name="pmid8948307">{{cite journal| author=Myklebust G, Gran JT| title=A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. | journal=Br J Rheumatol | year= 1996 | volume= 35 | issue= 11 | pages= 1161-8 | pmid=8948307 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8948307  }}</ref>
|
| style="background:#F5F5F5;" align="center" + |50s
* 50s
| style="background:#F5F5F5;" align="center" + |Diffuse
| colspan="2" |
* Diffuse
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
Line 551: Line 519:
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
|
| style="background:#F5F5F5;" align="left" + |
* [[Weight loss]]  
* [[Weight loss]]  
|
| style="background:#F5F5F5;" align="left" + |
* History of joints stiffness, worse in the morning  
* History of joints stiffness, worse in the morning  
|
| style="background:#F5F5F5;" align="left" + |
* Restricted shoulder motion  
* Restricted shoulder motion  
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑''' [[Erythrocyte sedimentation rate|ESR]]
* '''↑↑''' [[Erythrocyte sedimentation rate|ESR]]
* '''↑↑''' [[C-reactive protein|CRP]]
* '''↑↑''' [[C-reactive protein|CRP]]
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
|-
|-
Line 570: Line 538:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 590: Line 558:
! rowspan="5" style="background:#DCDCDC;" align="center" + |Genetic
! rowspan="5" style="background:#DCDCDC;" align="center" + |Genetic
! style="background:#DCDCDC;" align="center" + |[[Becker's muscular dystrophy|Becker muscular dystrophy]]<ref name="pmid25037084">{{cite journal |vauthors=Flanigan KM |title=Duchenne and Becker muscular dystrophies |journal=Neurol Clin |volume=32 |issue=3 |pages=671–88, viii |date=August 2014 |pmid=25037084 |doi=10.1016/j.ncl.2014.05.002 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Becker's muscular dystrophy|Becker muscular dystrophy]]<ref name="pmid25037084">{{cite journal |vauthors=Flanigan KM |title=Duchenne and Becker muscular dystrophies |journal=Neurol Clin |volume=32 |issue=3 |pages=671–88, viii |date=August 2014 |pmid=25037084 |doi=10.1016/j.ncl.2014.05.002 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |<13yrs
* <13yrs
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 601: Line 568:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Milder form of [[Duchenne muscular dystrophy|Duchenne]]
* Milder form of [[Duchenne muscular dystrophy|Duchenne]]
|
| style="background:#F5F5F5;" align="left" + |
* [[Growth delay]]
* [[Growth delay]]
* Age of onset of symptoms is much delayed than [[Duchenne muscular dystrophy|duchenne]]
* Age of onset of symptoms is much delayed than [[Duchenne muscular dystrophy|duchenne]]
|
| style="background:#F5F5F5;" align="left" + |
* Positive Grower sign
* Positive Grower sign
|
| style="background:#F5F5F5;" align="left" + |
* Decreased amount of [[dystrophin]].
* Decreased amount of [[dystrophin]].
|
| style="background:#F5F5F5;" align="left" + |
* ↑↑  
* ↑↑  
| rowspan="2" |
| rowspan="2" style="background:#F5F5F5;" align="left" + |
** Muscle fibril degeneration, regeneration
** Muscle fibril degeneration, regeneration
** Isolated fiber hypertrophy
** Isolated fiber hypertrophy
** Muscle replacement with fat and connective tissue
** Muscle replacement with fat and connective tissue
| rowspan="2" |
| rowspan="2" style="background:#F5F5F5;" align="left" + |
* [[Myopathic]]
* [[Myopathic]]
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Duchenne muscular dystrophy]]<ref name="pmid250370842">{{cite journal |vauthors=Flanigan KM |title=Duchenne and Becker muscular dystrophies |journal=Neurol Clin |volume=32 |issue=3 |pages=671–88, viii |date=August 2014 |pmid=25037084 |doi=10.1016/j.ncl.2014.05.002 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Duchenne muscular dystrophy]]<ref name="pmid250370842">{{cite journal |vauthors=Flanigan KM |title=Duchenne and Becker muscular dystrophies |journal=Neurol Clin |volume=32 |issue=3 |pages=671–88, viii |date=August 2014 |pmid=25037084 |doi=10.1016/j.ncl.2014.05.002 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |<13 yrs
* <13 yrs
| style="background:#F5F5F5;" align="center" + | Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + | Proximal
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
Line 631: Line 597:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
|
| style="background:#F5F5F5;" align="left" + |
* Calf psedohypertrophy
* Calf psedohypertrophy
* [[Cardiomyopathy]]
* [[Cardiomyopathy]]
* [[Kyphoscoliosis]]
* [[Kyphoscoliosis]]
* [[Cognitive impairment]]
* [[Cognitive impairment]]
|
| style="background:#F5F5F5;" align="left" + |
* Early onset
* Early onset
|
| style="background:#F5F5F5;" align="left" + |
* Positive Grower sign
* Positive Grower sign
|
| style="background:#F5F5F5;" align="left" + |
* Errors in the Xp21 gene.
* Errors in the Xp21 gene.
* Absence of [[dystrophin]].
* Absence of [[dystrophin]].
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Limb-girdle muscular dystrophy|Limb−girdle muscular]] dystrophies<ref name="pmid18769252">{{cite journal |vauthors=Guglieri M, Straub V, Bushby K, Lochmüller H |title=Limb-girdle muscular dystrophies |journal=Curr. Opin. Neurol. |volume=21 |issue=5 |pages=576–84 |date=October 2008 |pmid=18769252 |doi=10.1097/WCO.0b013e32830efdc2 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Limb-girdle muscular dystrophy|Limb−girdle muscular]] dystrophies<ref name="pmid18769252">{{cite journal |vauthors=Guglieri M, Straub V, Bushby K, Lochmüller H |title=Limb-girdle muscular dystrophies |journal=Curr. Opin. Neurol. |volume=21 |issue=5 |pages=576–84 |date=October 2008 |pmid=18769252 |doi=10.1097/WCO.0b013e32830efdc2 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |<15 yrs
* <15 yrs
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 661: Line 623:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Calf hypertrophy
* Calf hypertrophy
* Scapular winging
* Scapular winging
* [[Cardiomyopathy]]  
* [[Cardiomyopathy]]  
* [[Cardiac arrhythmia|Cardiac arrhythmias]]
* [[Cardiac arrhythmia|Cardiac arrhythmias]]
* Respiratory muscle weakness
* Respiratory muscle weakness
|
| style="background:#F5F5F5;" align="left" + |
* [[Autosomal dominant]]
* [[Autosomal dominant]]
* Deterioration of ability to run/walk  
* Deterioration of ability to run/walk  
|
| style="background:#F5F5F5;" align="left" + |
*[[Muscle weakness]] is generally symmetric 
*[[Muscle weakness]] is generally symmetric 
|
| style="background:#F5F5F5;" align="left" + |
* [[LMNA]] gene  
* [[LMNA]] gene  
* CAV3 gene
* CAV3 gene
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* [[Myopathic]]
* [[Myopathic]]
|-
|-
| style="background:#DCDCDC;" align="center" + |[[Myotonic dystrophy]]<ref name="pmid22995693">{{cite journal |vauthors=Udd B, Krahe R |title=The myotonic dystrophies: molecular, clinical, and therapeutic challenges |journal=Lancet Neurol |volume=11 |issue=10 |pages=891–905 |date=October 2012 |pmid=22995693 |doi=10.1016/S1474-4422(12)70204-1 |url=}}</ref>
| style="background:#DCDCDC;" align="center" + |[[Myotonic dystrophy]]<ref name="pmid22995693">{{cite journal |vauthors=Udd B, Krahe R |title=The myotonic dystrophies: molecular, clinical, and therapeutic challenges |journal=Lancet Neurol |volume=11 |issue=10 |pages=891–905 |date=October 2012 |pmid=22995693 |doi=10.1016/S1474-4422(12)70204-1 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |<18 years
* <18 years
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>distal
| colspan="2" |
* Proximal
 
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 698: Line 655:
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Myotonia]]
* [[Myotonia]]
* [[Cataracts]]
* [[Cataracts]]
Line 706: Line 663:
* [[Cholecystitis]]
* [[Cholecystitis]]
* [[Pregnancy]]
* [[Pregnancy]]
* Eyelid ptosis  
* Eyelid [[ptosis]]
|
| style="background:#F5F5F5;" align="left" + |
* Positive family history
* Positive family history
|
| style="background:#F5F5F5;" align="left" + |
* Muscles often contract and are unable to relax
* Muscles often contract and are unable to relax
|
| style="background:#F5F5F5;" align="left" + |
* Mutations in the [[DMPK]] gene
* Mutations in the [[DMPK]] gene
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* [[Myopathic]]
* [[Myopathic]]
|-
|-
| style="background:#DCDCDC;" align="center" + |[[Glycogen storage disease]]<ref name="pmid11957192">{{cite journal |vauthors=Kannourakis G |title=Glycogen storage disease |journal=Semin. Hematol. |volume=39 |issue=2 |pages=103–6 |date=April 2002 |pmid=11957192 |doi= |url=}}</ref>
| style="background:#DCDCDC;" align="center" + |[[Glycogen storage disease]]<ref name="pmid11957192">{{cite journal |vauthors=Kannourakis G |title=Glycogen storage disease |journal=Semin. Hematol. |volume=39 |issue=2 |pages=103–6 |date=April 2002 |pmid=11957192 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 732: Line 688:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Autosomal recessive|AR]]
* [[Autosomal recessive|AR]]
* [[Fatigue|Faituge]]
* [[Fatigue|Faituge]]
* [[Hypoglycemia]]
* [[Hypoglycemia]]
|
| style="background:#F5F5F5;" align="left" + |
* [[Exercise intolerance]]
* [[Exercise intolerance]]
|
| style="background:#F5F5F5;" align="left" + |
* [[Hypotonia]]
* [[Hypotonia]]
* [[Hepatomegaly]]
* [[Hepatomegaly]]
|
| style="background:#F5F5F5;" align="left" + |
* [[Lactic acidosis]]
* [[Lactic acidosis]]
* Elevated liver enzymes
* Elevated liver enzymes
* [[Ketosis]]
* [[Ketosis]]
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|-
|-
Line 757: Line 711:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 777: Line 731:
! rowspan="5" style="background:#DCDCDC;" align="center" + |Infectious
! rowspan="5" style="background:#DCDCDC;" align="center" + |Infectious
! style="background:#DCDCDC;" align="center" + |[[Lyme disease]]<ref name="pmid2795056">{{cite journal |vauthors=Schoenen J, Sianard-Gainko J, Carpentier M, Reznik M |title=Myositis during Borrelia burgdorferi infection (Lyme disease) |journal=J. Neurol. Neurosurg. Psychiatry |volume=52 |issue=8 |pages=1002–5 |date=August 1989 |pmid=2795056 |pmc=1031843 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Lyme disease]]<ref name="pmid2795056">{{cite journal |vauthors=Schoenen J, Sianard-Gainko J, Carpentier M, Reznik M |title=Myositis during Borrelia burgdorferi infection (Lyme disease) |journal=J. Neurol. Neurosurg. Psychiatry |volume=52 |issue=8 |pages=1002–5 |date=August 1989 |pmid=2795056 |pmc=1031843 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 788: Line 741:
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Erythema Migrans
* Erythema Migrans
* Flu−like symptoms
* Flu−like symptoms
* [[Lyme arthritis]]
* [[Lyme arthritis]]
* [[Neurological]] manifestations
* [[Neurological]] manifestations
|
| style="background:#F5F5F5;" align="left" + |
* H/o tick bite
* H/o tick bite
* Hiking trip
* Hiking trip
|
| style="background:#F5F5F5;" align="left" + |
* Target−like [[lesions]]
* Target−like [[lesions]]
* HSM
* HSM
|
| style="background:#F5F5F5;" align="left" + |
* Clinical diagnosis
* Clinical diagnosis
* +Serology
* +Serology
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Influenza]]<ref name="pmid6687269">{{cite journal |vauthors=Bove KE, Hilton PK, Partin J, Farrell MK |title=Morphology of acute myopathy associated with influenza B infection |journal=Pediatr Pathol |volume=1 |issue=1 |pages=51–66 |date=1983 |pmid=6687269 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Influenza]]<ref name="pmid6687269">{{cite journal |vauthors=Bove KE, Hilton PK, Partin J, Farrell MK |title=Morphology of acute myopathy associated with influenza B infection |journal=Pediatr Pathol |volume=1 |issue=1 |pages=51–66 |date=1983 |pmid=6687269 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + | style="background:#F5F5F5;" align="center" + |Negative
| colspan="2" style="background:#F5F5F5;" align="center" + |Negative
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + | +
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 821: Line 773:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
|
| style="background:#F5F5F5;" align="left" + |
* [[Fever]]
* [[Fever]]
* [[Malaise]]
* [[Malaise]]
* [[Rhinorrhea]]  
* [[Rhinorrhea]]  
* [[Muscle pain]] worse with movement
* [[Muscle pain]] worse with movement
|
| style="background:#F5F5F5;" align="left" + |
*Cold weather
*Cold weather
*H/o Ill contacts
*H/o Ill contacts
|
| style="background:#F5F5F5;" align="left" + |
* Muscle weakness, tenderness, and swelling.
* Muscle weakness, tenderness, and swelling.
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑''' Liver enzymes
* '''↑↑''' Liver enzymes
* +PCR
* Positive PCR
|
| style="background:#F5F5F5;" align="left" + |
* '''↑↑'''
* '''↑↑'''
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Polio]]<ref name="pmid15933355">{{cite journal |vauthors=Howard RS |title=Poliomyelitis and the postpolio syndrome |journal=BMJ |volume=330 |issue=7503 |pages=1314–8 |date=June 2005 |pmid=15933355 |pmc=558211 |doi=10.1136/bmj.330.7503.1314 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Polio]]<ref name="pmid15933355">{{cite journal |vauthors=Howard RS |title=Poliomyelitis and the postpolio syndrome |journal=BMJ |volume=330 |issue=7503 |pages=1314–8 |date=June 2005 |pmid=15933355 |pmc=558211 |doi=10.1136/bmj.330.7503.1314 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |<5 yrs
* <5 yrs
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" |
* Proximal
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 854: Line 804:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Asymmetrical [[paralysis]]
* Asymmetrical [[paralysis]]
* [[Muscle atrophy]]
* [[Muscle atrophy]]
* [[Tremors]]
* [[Tremors]]
* [[Skeletal]] deformities
* [[Skeletal]] deformities
|
| style="background:#F5F5F5;" align="left" + |
* History of skipped immunization.
* History of skipped immunization.
|
| style="background:#F5F5F5;" align="left" + |
* Normal  
* Normal  
* [[Meningeal signs]]
* [[Meningeal signs]]
* Asymmetrical flaccid paralysis
* Asymmetrical flaccid paralysis
* Pharyngeal paralysis
* Pharyngeal paralysis
|
| style="background:#F5F5F5;" align="left" + |
* Isolation from [[pharyngeal]]<nowiki/>secretions, CSF
* Isolation from [[pharyngeal]]<nowiki/>secretions, CSF
* +Serology
* Positive serology
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* Neurological pattern
* Neurological pattern
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Syphilis]]<ref name="pmid17235095">{{cite journal |vauthors=French P |title=Syphilis |journal=BMJ |volume=334 |issue=7585 |pages=143–7 |date=January 2007 |pmid=17235095 |pmc=1779891 |doi=10.1136/bmj.39085.518148.BE |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Syphilis]]<ref name="pmid17235095">{{cite journal |vauthors=French P |title=Syphilis |journal=BMJ |volume=334 |issue=7585 |pages=143–7 |date=January 2007 |pmid=17235095 |pmc=1779891 |doi=10.1136/bmj.39085.518148.BE |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Negative
| colspan="2" style="background:#F5F5F5;" align="center" + |Negative
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 888: Line 837:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Chancre]]
* [[Chancre]]
* [[Lymphadenopathy]]
* [[Lymphadenopathy]]
Line 894: Line 843:
* [[Neurosyphilis|Neuro syphilis]]
* [[Neurosyphilis|Neuro syphilis]]
* Cardiovascular syphilis
* Cardiovascular syphilis
|
| style="background:#F5F5F5;" align="left" + |
* History of risk factors (MSM, unprotected sex, multiple sex partners)
* History of risk factors (MSM, unprotected sex, multiple sex partners)
|
| style="background:#F5F5F5;" align="left" + |
* Non−tender [[chancre]] in primary syphilis.
* Non−tender [[chancre]] in primary syphilis.
* Followed by [[rash]]  
* Followed by [[rash]]  
* Generalized [[lymphadenopathy]] in secondary syphilis
* Generalized [[lymphadenopathy]] in secondary syphilis
|
| style="background:#F5F5F5;" align="left" + |
* Darkfield examinations
* Darkfield examinations
* VDRL
* VDRL
* RPR
* RPR
* [[FTA-ABS|FTA−ABS]]
* [[FTA-ABS|FTA−ABS]]
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Pyomyositis]]<ref name="pmid15380499">{{cite journal |vauthors=Crum NF |title=Bacterial pyomyositis in the United States |journal=Am. J. Med. |volume=117 |issue=6 |pages=420–8 |date=September 2004 |pmid=15380499 |doi=10.1016/j.amjmed.2004.03.031 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Pyomyositis]]<ref name="pmid15380499">{{cite journal |vauthors=Crum NF |title=Bacterial pyomyositis in the United States |journal=Am. J. Med. |volume=117 |issue=6 |pages=420–8 |date=September 2004 |pmid=15380499 |doi=10.1016/j.amjmed.2004.03.031 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>Distal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal<br>or<br>Distal
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
Line 924: Line 872:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Fever]]
* [[Fever]]
* [[Malaise]]
* [[Malaise]]
* [[Psoas abscess]]
* [[Psoas abscess]]
|
| style="background:#F5F5F5;" align="left" + |
* [[Immunocompromised]]
* [[Immunocompromised]]
|
| style="background:#F5F5F5;" align="left" + |
** Muscles are painful, swollen, tender, and indurated.
** Muscles are painful, swollen, tender, and indurated.
** Depending on the site of involvement, it may mimic appendicitis (psoas muscle), septic arthritis of the hip (iliacus muscle), or epidural abscess (piriformis muscle).
** Depending on the site of involvement, it may mimic appendicitis (psoas muscle), septic arthritis of the hip (iliacus muscle), or epidural abscess (piriformis muscle).
|
| style="background:#F5F5F5;" align="left" + |
* Leukocytosis
* Leukocytosis
* Elevated ESR
* Elevated ESR
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|-
|-
Line 946: Line 894:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 966: Line 914:
! rowspan="4" style="background:#DCDCDC;" align="center" + |Neurologic
! rowspan="4" style="background:#DCDCDC;" align="center" + |Neurologic
! style="background:#DCDCDC;" align="center" + |[[Amyotrophic lateral sclerosis|ALS]]<ref name="pmid26629397">{{cite journal |vauthors=Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A |title=A comprehensive review of amyotrophic lateral sclerosis |journal=Surg Neurol Int |volume=6 |issue= |pages=171 |date=2015 |pmid=26629397 |pmc=4653353 |doi=10.4103/2152-7806.169561 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Amyotrophic lateral sclerosis|ALS]]<ref name="pmid26629397">{{cite journal |vauthors=Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A |title=A comprehensive review of amyotrophic lateral sclerosis |journal=Surg Neurol Int |volume=6 |issue= |pages=171 |date=2015 |pmid=26629397 |pmc=4653353 |doi=10.4103/2152-7806.169561 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |>35
* >35
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>Distal
| colspan="2" |
* Proximal
* Distal
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 979: Line 925:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Dysphagia]]
* [[Dysphagia]]
* [[Spasticity]]
* [[Spasticity]]
* [[Hyperreflexia]]  
* [[Hyperreflexia]]  
* [[Babinski's sign|Babinski's]] +
* [[Babinski's sign|Babinski's]] +
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* Both [[Upper motor neurons|upper]] and [[lower motor neuron]] signs 
* Both [[Upper motor neurons|upper]] and [[lower motor neuron]] signs 
|
| style="background:#F5F5F5;" align="left" + |
* Clinical diagnosis
* Clinical diagnosis
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Nonspecific findings of chronic denervation with reinnervation
* Nonspecific findings of chronic denervation with reinnervation
|
| style="background:#F5F5F5;" align="left" + |
* Neuropathic  
* Neuropathic  
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Stroke]]<ref name="pmid20412000">{{cite journal |vauthors=Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S |title=Acute ischemic stroke update |journal=Pharmacotherapy |volume=30 |issue=5 |pages=493–514 |date=May 2010 |pmid=20412000 |doi=10.1592/phco.30.5.493 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Stroke]]<ref name="pmid20412000">{{cite journal |vauthors=Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S |title=Acute ischemic stroke update |journal=Pharmacotherapy |volume=30 |issue=5 |pages=493–514 |date=May 2010 |pmid=20412000 |doi=10.1592/phco.30.5.493 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |>65
* >65
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>distal
| colspan="2" |
* Proximal
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 1,011: Line 954:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Dysphagia]]
* [[Dysphagia]]
* Unilateral/Bilateral weakness
* Unilateral/Bilateral weakness
|
| style="background:#F5F5F5;" align="left" + |
* H/o [[Hypertension|HTN]], [[dyslipidaemia]] [[Diabetes mellitus|DM]]
* H/o [[Hypertension|HTN]], [[dyslipidaemia]] [[Diabetes mellitus|DM]]
|
| style="background:#F5F5F5;" align="left" + |
* Weakness of the involved arm
* Weakness of the involved arm
|
| style="background:#F5F5F5;" align="left" + |
*Head CT
*Head CT
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Neuropathic
* Neuropathic
|-
|-
! style="background:#DCDCDC;" align="center" + |[[GBS]]<ref name="pmid23628447">{{cite journal |vauthors=van Doorn PA |title=Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) |journal=Presse Med |volume=42 |issue=6 Pt 2 |pages=e193–201 |date=June 2013 |pmid=23628447 |doi=10.1016/j.lpm.2013.02.328 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[GBS]]<ref name="pmid23628447">{{cite journal |vauthors=van Doorn PA |title=Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS) |journal=Presse Med |volume=42 |issue=6 Pt 2 |pages=e193–201 |date=June 2013 |pmid=23628447 |doi=10.1016/j.lpm.2013.02.328 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |18  −350
* 18  −350
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 1,039: Line 981:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Ascending paralysis]]
* [[Ascending paralysis]]
|
| style="background:#F5F5F5;" align="left" + |
* Precedes a [[Gastrointestinal diseases|gastrointestinal disease]]
* Precedes a [[Gastrointestinal diseases|gastrointestinal disease]]
|
| style="background:#F5F5F5;" align="left" + |
* Weakness of lower extremities followed by upper extremities
* Weakness of lower extremities followed by upper extremities
|
| style="background:#F5F5F5;" align="left" + |
* Cytologic albumin ratio
* Cytologic albumin ratio
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* Neuropathic
* Neuropathic
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Multiple sclerosis|Multiple Sclerosis]]<ref name="pmid22605909">{{cite journal |vauthors=Goldenberg MM |title=Multiple sclerosis review |journal=P T |volume=37 |issue=3 |pages=175–84 |date=March 2012 |pmid=22605909 |pmc=3351877 |doi= |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Multiple sclerosis|Multiple Sclerosis]]<ref name="pmid22605909">{{cite journal |vauthors=Goldenberg MM |title=Multiple sclerosis review |journal=P T |volume=37 |issue=3 |pages=175–84 |date=March 2012 |pmid=22605909 |pmc=3351877 |doi= |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |30's
* 30's
| style="background:#F5F5F5;" align="center" + |Proximal<br>&<br>distal
| colspan="2" |
* Proximal
* Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 1,068: Line 1,007:
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Ocular findings
* Ocular findings
* [[Urinary incontinence]]
* [[Urinary incontinence]]
* Problems with [[Speech and language pathology|speech]] or [[swallowing]]
* Problems with [[Speech and language pathology|speech]] or [[swallowing]]
|
| style="background:#F5F5F5;" align="left" + |
* Attacks or exacerbation
* Attacks or exacerbation
|
| style="background:#F5F5F5;" align="left" + |
** Localized weakness
** Localized weakness
** Focal sensory disturbances
** Focal sensory disturbances
** Hyper reactive reflexes  
** Hyper reactive reflexes  
** Increased tone or stiffness
** Increased tone or stiffness
|
| style="background:#F5F5F5;" align="left" + |
* Head CT ologo−clonal bands
* Head CT ologo−clonal bands
|
| style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
|
| style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
|
| style="background:#F5F5F5;" align="left" + |
* Neuropathic
* Neuropathic
|-
|-
Line 1,091: Line 1,030:
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Disease
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Age of onset
! colspan="2" style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Muscle weakness
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Fever
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
! style="background:#4479BA; color: #FFFFFF;" align="center" + |Myalgia
Line 1,111: Line 1,050:
! rowspan="3" style="background:#DCDCDC;" align="center" + |Neuromuscular
! rowspan="3" style="background:#DCDCDC;" align="center" + |Neuromuscular
! style="background:#DCDCDC;" align="center" + |[[Botulinum]]<ref name="pmid15257512">{{cite journal |vauthors=Cherington M |title=Botulism: update and review |journal=Semin Neurol |volume=24 |issue=2 |pages=155–63 |date=June 2004 |pmid=15257512 |doi=10.1055/s-2004-830901 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Botulinum]]<ref name="pmid15257512">{{cite journal |vauthors=Cherington M |title=Botulism: update and review |journal=Semin Neurol |volume=24 |issue=2 |pages=155–63 |date=June 2004 |pmid=15257512 |doi=10.1055/s-2004-830901 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Distal
| colspan="2" style="background:#F5F5F5;" align="center" + |Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
Line 1,122: Line 1,060:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
|
| style="background:#F5F5F5;" align="left" + |
* [[Double vision]]
* [[Double vision]]
* [[Blurred vision]]
* [[Blurred vision]]
Line 1,128: Line 1,066:
* [[Slurred speech]]
* [[Slurred speech]]
* [[Difficulty swallowing]]
* [[Difficulty swallowing]]
|
| style="background:#F5F5F5;" align="left" + |
* H/O food exposure   
* H/O food exposure   
| rowspan="3" |
| rowspan="3" style="background:#F5F5F5;" align="left" + |
* [[Hyporeflexia]]
* [[Hyporeflexia]]
* Decreased strength
* Decreased strength
|
| style="background:#F5F5F5;" align="left" + |
* +Toxin
* +Toxin
| rowspan="3" |
| rowspan="3" style="background:#F5F5F5;" align="left" + |
* Normal
* Normal
| rowspan="3" |
| rowspan="3" style="background:#F5F5F5;" align="left" + |
* N/A
* N/A
| rowspan="3" |
| rowspan="3" style="background:#F5F5F5;" align="left" + |
* Myopathic
* Myopathic
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Lambert-Eaton syndrome|Lambert−Eaton syndrome]]<ref name="pmid22094130">{{cite journal |vauthors=Titulaer MJ, Lang B, Verschuuren JJ |title=Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies |journal=Lancet Neurol |volume=10 |issue=12 |pages=1098–107 |date=December 2011 |pmid=22094130 |doi=10.1016/S1474-4422(11)70245-9 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Lambert-Eaton syndrome|Lambert−Eaton syndrome]]<ref name="pmid22094130">{{cite journal |vauthors=Titulaer MJ, Lang B, Verschuuren JJ |title=Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies |journal=Lancet Neurol |volume=10 |issue=12 |pages=1098–107 |date=December 2011 |pmid=22094130 |doi=10.1016/S1474-4422(11)70245-9 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Distal
| colspan="2" style="background:#F5F5F5;" align="center" + |Distal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
Line 1,154: Line 1,091:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* Weakness of the bulbar muscles
* Weakness of the bulbar muscles
* Ocular
* Ocular
* Limb weakness
* Limb weakness
|
| style="background:#F5F5F5;" align="left" + |
* Weaknessa is often relieved temporarily after exertion or physical exercise.
* Weaknessa is often relieved temporarily after exertion or physical exercise.
|
| style="background:#F5F5F5;" align="left" + |
* Antibodies against voltage−gated calcium channels 
* Antibodies against voltage−gated calcium channels 
|-
|-
! style="background:#DCDCDC;" align="center" + |[[Myasthenia gravis]]<ref name="pmid23193443">{{cite journal |vauthors=Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J |title=Myasthenia gravis: a review |journal=Autoimmune Dis |volume=2012 |issue= |pages=874680 |date=2012 |pmid=23193443 |pmc=3501798 |doi=10.1155/2012/874680 |url=}}</ref>
! style="background:#DCDCDC;" align="center" + |[[Myasthenia gravis]]<ref name="pmid23193443">{{cite journal |vauthors=Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J |title=Myasthenia gravis: a review |journal=Autoimmune Dis |volume=2012 |issue= |pages=874680 |date=2012 |pmid=23193443 |pmc=3501798 |doi=10.1155/2012/874680 |url=}}</ref>
|
| style="background:#F5F5F5;" align="center" + |Variable
* Variable
| style="background:#F5F5F5;" align="center" + |Proximal
| colspan="2" style="background:#F5F5F5;" align="center" + |Proximal
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + | −
| style="background:#F5F5F5;" align="center" + | −
Line 1,175: Line 1,111:
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |<nowiki>+</nowiki>
| style="background:#F5F5F5;" align="center" + |−
| style="background:#F5F5F5;" align="center" + |−
|
| style="background:#F5F5F5;" align="left" + |
* [[Ocular]]
* [[Ocular]]
* [[Bulbar]] 
* [[Bulbar]] 
* Limb weakness
* Limb weakness
* Isolated neck, limbs and respiratory weakness
* Isolated neck, limbs and respiratory weakness
|
| style="background:#F5F5F5;" align="left" + |
* Weakness often worsens with activity  
* Weakness often worsens with activity  
|
| style="background:#F5F5F5;" align="left" + |
* Antibodies that block or destroy nicotinic [[acetylcholine receptors]] 
* Antibodies that block or destroy nicotinic [[acetylcholine receptors]] 
|}
|}

Revision as of 13:59, 11 April 2018


Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Flow chart

Approach to muscle weakness[1][2]

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Objective Muscle weakness
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Malignancy
Arthralgia
Anemia
Firbomyalgia
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Generalized
 
 
 
 
 
 
 
 
 
 
 
 
 
Localized
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myasthenia gravis
Periodic paralysis
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asymmetric
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Symmetric
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cerebrovascular accidents
Demyleinating disorders
Atrophy
Mononeuropathy
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Specific pattern
 
 
 
 
 
 
 
Specific pattern
 
 
 
 
 
 
 
Proximal
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hereditary neuropathy
Muscular dystrophy
 
 
 
 
 
 
 
Myoapthy
Duchenne muscular dystrophy
 
 
 
 
 
 
 
Motor neuron disease
Peripheral neuropathy
 
 
 

Differentiating Various Muscle Weakness

Organ system Disease Symptoms History Physical

Examination

Diagnosis
Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Medication−induced Corticosteroids[3] Variable Proximal + +
  • Positive h/o medications
  • Facial and sphincter muscles are usually spared
  • Normal
  • Normal
  • Normal
Statins[4] 60+ Proximal + −/+(Rhabdomyolysis)
  • N/A
  • Positive h/o medications
  • H/o other medication use
  • ↑↑ Liver enzymes
  • ↑↑
  • Necrosis
  • Degeneration, and regeneration of fibers
  • Phagocytic infiltration
  • Normal
Alcohol[5] Variable Proximal + +/−
  • Monspecific and are normal in many patients
  • Normal or ↑↑
  • Normal
  • Normal
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Endocrine Cushing's disease[6] 25 −45 Proximal +
  • N/A
  • Normal
  • Atrophy of type 2 muscle fibers, especially type 2B
Normal
Adrenal insufficiency[7] 30−50 years Proximal + +
  • Auricular−cartilage calcification 
  • Normal
  • Normal
  • Normal
Hyperaldosteronism with myopathy[8] 50 Proximal
&
distal
+

Rhabdomyolysis

  • Normal
  • Normal
  • Normal
Hyperthyroidism[9] 40 Proximal + + +
  • ↑↑
  • Non specific
Hypothyroidism[10] 55 Proximal + + + + + Rhabdomyolysis
  • ↑↑
  • Nonspecific 
  • Normal
Diabetic infraction[11] 45  Proximal + + + +
  • Normal
  • Normal
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Inflammatory/ Rheumatologic Dermatomyositis[12] 40s−50s
Can affect children
Proximal + + +
  • ↑↑
  • Perimysial mononuclear infiltrate
Polymyositis[13] > 18 years Proximal + + +
  • N/A
  • N/A
  • ↑↑
  • Endomysial mononuclear infiltrate
  • Patchy necrosis
Inclusion body myositis[14] 50s Proximal
&
distal
  • N/A
  • Antibodies to cytoplasmic 5'−nucleotidase
  • ↑↑
Fibromyalgia[15] 40−50s Generalized +
  • Normal
  • Normal
  • Normal
  • Normal
Polymyalgia Rheumatica[16] 50s Diffuse + + +
  • History of joints stiffness, worse in the morning
  • Restricted shoulder motion
  • Normal
  • Normal
  • Normal
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Genetic Becker muscular dystrophy[17] <13yrs Proximal + + +
  • Positive Grower sign
  • ↑↑
    • Muscle fibril degeneration, regeneration
    • Isolated fiber hypertrophy
    • Muscle replacement with fat and connective tissue
Duchenne muscular dystrophy[18] <13 yrs Proximal + + +
  • Early onset
  • Positive Grower sign
  • ↑↑
Limb−girdle muscular dystrophies[19] <15 yrs Proximal + + + +
  • LMNA gene
  • CAV3 gene
  • ↑↑
  • N/A
Myotonic dystrophy[20] <18 years Proximal
&
distal
+ + +
  • Positive family history
  • Muscles often contract and are unable to relax
  • Mutations in the DMPK gene
  • N/A
  • N/A
Glycogen storage disease[21] Variable Proximal +
  • ↑↑
  • Normal
  • Normal
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Infectious Lyme disease[22] Variable Proximal + + +/− +
  • H/o tick bite
  • Hiking trip
  • Clinical diagnosis
  • +Serology
  • N/A
  • N/A
  • N/A
Influenza[23] Variable style="background:#F5F5F5;" align="center" + |Negative + + + +
  • Cold weather
  • H/o Ill contacts
  • Muscle weakness, tenderness, and swelling.
  • ↑↑ Liver enzymes
  • Positive PCR
  • ↑↑
  • N/A
  • N/A
Polio[24] <5 yrs Proximal + + +
  • History of skipped immunization.
  • Isolation from pharyngealsecretions, CSF
  • Positive serology
  • N/A
  • N/A
  • Neurological pattern
Syphilis[25] Variable Negative + +
  • History of risk factors (MSM, unprotected sex, multiple sex partners)
  • N/A
  • N/A
  • N/A
Pyomyositis[26] Variable Proximal
&
Distal
+ + +
    • Muscles are painful, swollen, tender, and indurated.
    • Depending on the site of involvement, it may mimic appendicitis (psoas muscle), septic arthritis of the hip (iliacus muscle), or epidural abscess (piriformis muscle).
  • Leukocytosis
  • Elevated ESR
  • N/A
  • N/A
  • N/A
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Neurologic ALS[27] >35 Proximal
&
Distal
  • Distal
+ + +
  • N/A
  • Clinical diagnosis
  • Normal
  • Nonspecific findings of chronic denervation with reinnervation
  • Neuropathic
Stroke[28] >65 Proximal
&
distal
+ + +
  • Weakness of the involved arm
  • Head CT
  • Normal
  • Normal
  • Neuropathic
GBS[29] 18 −350 Proximal + +
  • Weakness of lower extremities followed by upper extremities
  • Cytologic albumin ratio
  • Normal
  • Normal
  • Neuropathic
Multiple Sclerosis[30] 30's Proximal
&
distal
+ +
  • Attacks or exacerbation
    • Localized weakness
    • Focal sensory disturbances
    • Hyper reactive reflexes
    • Increased tone or stiffness
  • Head CT ologo−clonal bands
  • Normal
  • N/A
  • Neuropathic
Organ system Disease Age of onset Muscle weakness Fever Myalgia Contractures Gait abnormality Neuropathy Atrophy Stiffness Myoglobinuria Other features History Physical

Examination

Laboratory Findings Creatine Kinase Muscle Biopsy Electromyogram
Neuromuscular Botulinum[31] Variable Distal + +
  • H/O food exposure
  • +Toxin
  • Normal
  • N/A
  • Myopathic
Lambert−Eaton syndrome[32] Variable Distal + + +
  • Weakness of the bulbar muscles
  • Ocular
  • Limb weakness
  • Weaknessa is often relieved temporarily after exertion or physical exercise.
  • Antibodies against voltage−gated calcium channels 
Myasthenia gravis[33] Variable Proximal + + +
  • Ocular
  • Bulbar 
  • Limb weakness
  • Isolated neck, limbs and respiratory weakness
  • Weakness often worsens with activity

References

  1. Jackson CE (April 2008). "A clinical approach to muscle diseases". Semin Neurol. 28 (2): 228–40. doi:10.1055/s-2008-1062266. PMID 18351524.
  2. LoVecchio F, Jacobson S (August 1997). "Approach to generalized weakness and peripheral neuromuscular disease". Emerg. Med. Clin. North Am. 15 (3): 605–23. PMID 9255135.
  3. Gupta A, Gupta Y (September 2013). "Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment". Indian J Endocrinol Metab. 17 (5): 913–6. doi:10.4103/2230-8210.117215. PMC 3784879. PMID 24083177.
  4. Tomaszewski M, Stępień KM, Tomaszewska J, Czuczwar SJ (2011). "Statin-induced myopathies". Pharmacol Rep. 63 (4): 859–66. PMID 22001973.
  5. Preedy VR, Adachi J, Ueno Y, Ahmed S, Mantle D, Mullatti N, Rajendram R, Peters TJ (November 2001). "Alcoholic skeletal muscle myopathy: definitions, features, contribution of neuropathy, impact and diagnosis". Eur. J. Neurol. 8 (6): 677–87. PMID 11784353.
  6. Sharma V, Borah P, Basumatary LJ, Das M, Goswami M, Kayal AK (July 2014). "Myopathies of endocrine disorders: A prospective clinical and biochemical study". Ann Indian Acad Neurol. 17 (3): 298–302. doi:10.4103/0972-2327.138505. PMC 4162016. PMID 25221399.
  7. Ruff RL, Weissmann J (August 1988). "Endocrine myopathies". Neurol Clin. 6 (3): 575–92. PMID 3065602.
  8. Sambrook MA, Heron JR, Aber GM (April 1972). "Myopathy in association with primary hyperaldosteronism". J. Neurol. Neurosurg. Psychiatry. 35 (2): 202–7. PMC 494037. PMID 5037033.
  9. Li Q, Liu Y, Zhang Q, Tian H, Li J, Li S (July 2017). "Myopathy in hyperthyroidism as a consequence of rapid reduction of thyroid hormone: A case report". Medicine (Baltimore). 96 (30): e7591. doi:10.1097/MD.0000000000007591. PMC 5627834. PMID 28746208.
  10. Khaleeli AA, Griffith DG, Edwards RH (September 1983). "The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle". Clin. Endocrinol. (Oxf). 19 (3): 365–76. PMID 6627693.
  11. Horton WB, Taylor JS, Ragland TJ, Subauste AR (2015). "Diabetic muscle infarction: a systematic review". BMJ Open Diabetes Res Care. 3 (1): e000082. doi:10.1136/bmjdrc-2015-000082. PMC 4410119. PMID 25932331.
  12. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  13. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  14. Dalakas MC (1991). "Polymyositis, dermatomyositis and inclusion-body myositis". N Engl J Med. 325 (21): 1487–98. doi:10.1056/NEJM199111213252107. PMID 1658649.
  15. Ohara N, Katada S, Yamada T, Mezaki N, Suzuki H, Suzuki A, Hanyu O, Yoneoka Y, Kawachi I, Shimohata T, Kakita A, Nishizawa M, Sone H (2016). "Fibromyalgia in a Patient with Cushing's Disease Accompanied by Central Hypothyroidism". Intern. Med. 55 (21): 3185–3190. doi:10.2169/internalmedicine.55.5926. PMC 5140872. PMID 27803417.
  16. Myklebust G, Gran JT (1996). "A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis". Br J Rheumatol. 35 (11): 1161–8. PMID 8948307.
  17. Flanigan KM (August 2014). "Duchenne and Becker muscular dystrophies". Neurol Clin. 32 (3): 671–88, viii. doi:10.1016/j.ncl.2014.05.002. PMID 25037084.
  18. Flanigan KM (August 2014). "Duchenne and Becker muscular dystrophies". Neurol Clin. 32 (3): 671–88, viii. doi:10.1016/j.ncl.2014.05.002. PMID 25037084.
  19. Guglieri M, Straub V, Bushby K, Lochmüller H (October 2008). "Limb-girdle muscular dystrophies". Curr. Opin. Neurol. 21 (5): 576–84. doi:10.1097/WCO.0b013e32830efdc2. PMID 18769252.
  20. Udd B, Krahe R (October 2012). "The myotonic dystrophies: molecular, clinical, and therapeutic challenges". Lancet Neurol. 11 (10): 891–905. doi:10.1016/S1474-4422(12)70204-1. PMID 22995693.
  21. Kannourakis G (April 2002). "Glycogen storage disease". Semin. Hematol. 39 (2): 103–6. PMID 11957192.
  22. Schoenen J, Sianard-Gainko J, Carpentier M, Reznik M (August 1989). "Myositis during Borrelia burgdorferi infection (Lyme disease)". J. Neurol. Neurosurg. Psychiatry. 52 (8): 1002–5. PMC 1031843. PMID 2795056.
  23. Bove KE, Hilton PK, Partin J, Farrell MK (1983). "Morphology of acute myopathy associated with influenza B infection". Pediatr Pathol. 1 (1): 51–66. PMID 6687269.
  24. Howard RS (June 2005). "Poliomyelitis and the postpolio syndrome". BMJ. 330 (7503): 1314–8. doi:10.1136/bmj.330.7503.1314. PMC 558211. PMID 15933355.
  25. French P (January 2007). "Syphilis". BMJ. 334 (7585): 143–7. doi:10.1136/bmj.39085.518148.BE. PMC 1779891. PMID 17235095.
  26. Crum NF (September 2004). "Bacterial pyomyositis in the United States". Am. J. Med. 117 (6): 420–8. doi:10.1016/j.amjmed.2004.03.031. PMID 15380499.
  27. Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, Pagani W, Lodin D, Orozco G, Chinea A (2015). "A comprehensive review of amyotrophic lateral sclerosis". Surg Neurol Int. 6: 171. doi:10.4103/2152-7806.169561. PMC 4653353. PMID 26629397.
  28. Baldwin K, Orr S, Briand M, Piazza C, Veydt A, McCoy S (May 2010). "Acute ischemic stroke update". Pharmacotherapy. 30 (5): 493–514. doi:10.1592/phco.30.5.493. PMID 20412000.
  29. van Doorn PA (June 2013). "Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS)". Presse Med. 42 (6 Pt 2): e193–201. doi:10.1016/j.lpm.2013.02.328. PMID 23628447.
  30. Goldenberg MM (March 2012). "Multiple sclerosis review". P T. 37 (3): 175–84. PMC 3351877. PMID 22605909.
  31. Cherington M (June 2004). "Botulism: update and review". Semin Neurol. 24 (2): 155–63. doi:10.1055/s-2004-830901. PMID 15257512.
  32. Titulaer MJ, Lang B, Verschuuren JJ (December 2011). "Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies". Lancet Neurol. 10 (12): 1098–107. doi:10.1016/S1474-4422(11)70245-9. PMID 22094130.
  33. Jayam Trouth A, Dabi A, Solieman N, Kurukumbi M, Kalyanam J (2012). "Myasthenia gravis: a review". Autoimmune Dis. 2012: 874680. doi:10.1155/2012/874680. PMC 3501798. PMID 23193443.